| Allergic Conjunctivitis
Alrex vs Bepreve
Side-by-side clinical, coverage, and cost comparison for allergic conjunctivitis.Deep comparison between: Alrex vs Bepreve with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBepreve has a higher rate of injection site reactions vs Alrex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Bepreve but not Alrex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alrex
Bepreve
At A Glance
Ophthalmic
Four times daily
Ophthalmic corticosteroid
Ophthalmic
Twice daily
H1-receptor antagonist
Indications
- Allergic Conjunctivitis
- Allergic Conjunctivitis
Dosing
Allergic Conjunctivitis One drop instilled into the affected eye(s) four times daily; shake vigorously before using.
Allergic Conjunctivitis Instill one drop into the affected eye(s) twice a day; remove contact lenses prior to instillation.
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
- Known or suspected hypersensitivity to any ingredient in this preparation or to other corticosteroids
- History of hypersensitivity reactions to bepotastine or any of the other ingredients
Adverse Reactions
Most common (>=5%) abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, photophobia
Serious elevated intraocular pressure, optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection, globe perforation
Other ocular (<5%) conjunctivitis, corneal abnormalities, eyelid erythema, keratoconjunctivitis, ocular irritation/pain/discomfort, papillae, uveitis
Non-ocular (<15%) headache, rhinitis, pharyngitis
Most common (>=25%) Mild taste following instillation
Common (2-5%) Eye irritation, headache, nasopharyngitis
Postmarketing Hypersensitivity reactions including itching, body rash, and swelling of lips, tongue and/or throat
Pharmacology
Loteprednol etabonate is an ophthalmic corticosteroid that inhibits the inflammatory response by inducing phospholipase A2 inhibitory proteins (lipocortins), thereby reducing biosynthesis of prostaglandins and leukotrienes; it is structurally modified from prednisolone-related compounds to undergo predictable metabolism to inactive carboxylic acid metabolites.
Bepotastine is a topically active, direct H1-receptor antagonist and inhibitor of histamine release from mast cells, administered as an ophthalmic solution for allergic conjunctivitis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alrex
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (0/12) · Qty limit (0/12)
Bepreve
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Alrex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Bepreve
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Alrex
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Bepreve
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Alrex.
No savings programs available for Bepreve.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BepreveView full Bepreve profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.